# PDS Biotechnology Corp: financial statements, quarterly

PDSB · Nasdaq · CIK 1472091 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/pdsb.md) · [Financials](/companies/pdsb/financials.md) · [Filings](/companies/pdsb/filings.md) · [Insiders](/companies/pdsb/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/pdsb/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [6.4](/filings/0001140361-24-046891.md) | [7.5 d](/filings/0001140361-25-010717.md) | [6.7](/filings/0001140361-25-018967.md) | [4.5](/filings/0001140361-25-030825.md) | [6.8](/filings/0001140361-25-041976.md) | [4.5 d](/filings/0001140361-26-012030.md) | [5.8](/filings/0001140361-26-021286.md) | [4.2](/filings/0001140361-26-032824.md) | [4.6](/filings/0001140361-25-041976.md) | [4.4 d](/filings/0001140361-26-012030.md) | [3.5](/filings/0001140361-26-021286.md) | [3.3](/filings/0001140361-26-032824.md) |
| Operating income | $m | [(10.5)](/filings/0001140361-24-046891.md) | [(10.4) d](/filings/0001140361-25-010717.md) | [(10.1)](/filings/0001140361-25-018967.md) | [(8.7)](/filings/0001140361-25-030825.md) | [(10.2)](/filings/0001140361-25-041976.md) | [(7.4) d](/filings/0001140361-26-012030.md) | [(9.1)](/filings/0001140361-26-021286.md) | [(7.6)](/filings/0001140361-26-032824.md) | [(8.1)](/filings/0001140361-25-041976.md) | [(6.7) d](/filings/0001140361-26-012030.md) | [(6.5)](/filings/0001140361-26-021286.md) | [(6.5)](/filings/0001140361-26-032824.md) |
| Interest expense | $m | [1.1](/filings/0001140361-23-053242.md) | [1.2 d](/filings/0001140361-24-016265.md) | [1.2](/filings/0001140361-24-026295.md) | [1.2](/filings/0001140361-25-030825.md) | [1.2](/filings/0001140361-25-041976.md) | [1.1 d](/filings/0001140361-26-012030.md) | [0.9](/filings/0001140361-26-021286.md) | [2.1](/filings/0001140361-26-032824.md) | [1.2](/filings/0001140361-25-041976.md) | [1.1 d](/filings/0001140361-26-012030.md) | [1.0](/filings/0001140361-26-021286.md) | [3.4](/filings/0001140361-26-032824.md) |
| Income tax | $m | [0.0](/filings/0001140361-24-046891.md) | [0.0 d](/filings/0001140361-25-010717.md) | [0.0](/filings/0001140361-25-018967.md) | [(0.9)](/filings/0001140361-25-030825.md) | [0.0](/filings/0001140361-25-041976.md) | [0.0 d](/filings/0001140361-26-012030.md) | [(1.2)](/filings/0001140361-26-021286.md) | [0.0](/filings/0001140361-26-032824.md) | [0.0](/filings/0001140361-25-041976.md) | [0.0 d](/filings/0001140361-26-012030.md) | [0.0](/filings/0001140361-26-021286.md) | [0.0](/filings/0001140361-26-032824.md) |
| Net income | $m | [(10.8)](/filings/0001140361-25-010717.md) | [(10.9)](/filings/0001140361-25-010717.md) | [(10.6)](/filings/0001140361-26-012030.md) | [(8.3)](/filings/0001140361-26-012030.md) | [(10.7)](/filings/0001140361-26-012030.md) | [(8.0)](/filings/0001140361-26-012030.md) | [(8.5)](/filings/0001140361-26-032824.md) | [(9.4)](/filings/0001140361-26-032824.md) | [(9.0)](/filings/0001140361-26-012030.md) | [(7.6)](/filings/0001140361-26-012030.md) | [(7.3)](/filings/0001140361-26-032824.md) | [(9.8)](/filings/0001140361-26-032824.md) |
| Diluted EPS | $ per share | [(0.35)](/filings/0001140361-24-046891.md) | not reported | [(0.30)](/filings/0001140361-25-018967.md) | [(0.23)](/filings/0001140361-25-030825.md) | [(0.29)](/filings/0001140361-25-041976.md) | not reported | [(0.21)](/filings/0001140361-26-021286.md) | [(0.21)](/filings/0001140361-26-032824.md) | [(0.19)](/filings/0001140361-25-041976.md) | not reported | [(0.13)](/filings/0001140361-26-021286.md) | [(0.18)](/filings/0001140361-26-032824.md) |
| Basic EPS | $ per share | [(0.35)](/filings/0001140361-24-046891.md) | not reported | [(0.30)](/filings/0001140361-25-018967.md) | [(0.23)](/filings/0001140361-25-030825.md) | [(0.29)](/filings/0001140361-25-041976.md) | not reported | [(0.21)](/filings/0001140361-26-021286.md) | [(0.21)](/filings/0001140361-26-032824.md) | [(0.19)](/filings/0001140361-25-041976.md) | not reported | [(0.13)](/filings/0001140361-26-021286.md) | [(0.18)](/filings/0001140361-26-032824.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [54.3](/filings/0001140361-23-053242.md) | [56.6](/filings/0001140361-25-010717.md) | [66.6](/filings/0001140361-24-026295.md) | [57.7](/filings/0001140361-24-037067.md) | [49.8](/filings/0001140361-24-046891.md) | [41.7](/filings/0001140361-26-012030.md) | [40.0](/filings/0001140361-25-018967.md) | [31.9](/filings/0001140361-25-030825.md) | [26.2](/filings/0001140361-25-041976.md) | [26.7](/filings/0001140361-26-032824.md) | [21.7](/filings/0001140361-26-021286.md) | [5.6](/filings/0001140361-26-032824.md) |
| Current assets | $m | [56.8](/filings/0001140361-23-053242.md) | [59.1](/filings/0001140361-25-010717.md) | [68.7](/filings/0001140361-24-026295.md) | [60.2](/filings/0001140361-24-037067.md) | [52.1](/filings/0001140361-24-046891.md) | [45.1](/filings/0001140361-26-012030.md) | [42.5](/filings/0001140361-25-018967.md) | [33.6](/filings/0001140361-25-030825.md) | [27.9](/filings/0001140361-25-041976.md) | [28.3](/filings/0001140361-26-032824.md) | [22.9](/filings/0001140361-26-021286.md) | [7.0](/filings/0001140361-26-032824.md) |
| Total assets | $m | [57.2](/filings/0001140361-23-053242.md) | [59.4](/filings/0001140361-25-010717.md) | [69.0](/filings/0001140361-24-026295.md) | [60.5](/filings/0001140361-24-037067.md) | [52.5](/filings/0001140361-24-046891.md) | [45.4](/filings/0001140361-26-012030.md) | [47.0](/filings/0001140361-25-018967.md) | [40.5](/filings/0001140361-25-030825.md) | [34.7](/filings/0001140361-25-041976.md) | [30.5](/filings/0001140361-26-032824.md) | [24.7](/filings/0001140361-26-021286.md) | [8.8](/filings/0001140361-26-032824.md) |
| Current liabilities | $m | [9.2](/filings/0001140361-23-053242.md) | [13.6](/filings/0001140361-25-010717.md) | [15.1](/filings/0001140361-24-026295.md) | [15.7](/filings/0001140361-24-037067.md) | [18.3](/filings/0001140361-24-046891.md) | [17.1](/filings/0001140361-26-012030.md) | [18.3](/filings/0001140361-25-018967.md) | [11.5](/filings/0001140361-25-030825.md) | [13.3](/filings/0001140361-25-041976.md) | [9.5](/filings/0001140361-26-032824.md) | [10.1](/filings/0001140361-26-021286.md) | [12.4](/filings/0001140361-26-032824.md) |
| Total liabilities | $m | [32.7](/filings/0001140361-23-053242.md) | [33.3](/filings/0001140361-25-010717.md) | [31.8](/filings/0001140361-24-026295.md) | [29.6](/filings/0001140361-24-037067.md) | [30.4](/filings/0001140361-24-046891.md) | [26.4](/filings/0001140361-26-012030.md) | [24.7](/filings/0001140361-25-018967.md) | [24.5](/filings/0001140361-25-030825.md) | [25.3](/filings/0001140361-25-041976.md) | [21.2](/filings/0001140361-26-032824.md) | [20.8](/filings/0001140361-26-021286.md) | [12.4](/filings/0001140361-26-032824.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [24.5](/filings/0001140361-25-010717.md) | [26.1](/filings/0001140361-26-012030.md) | [37.2](/filings/0001140361-26-012030.md) | [30.9](/filings/0001140361-26-012030.md) | [22.0](/filings/0001140361-26-012030.md) | [19.0](/filings/0001140361-26-032824.md) | [22.4](/filings/0001140361-26-032824.md) | [16.0](/filings/0001140361-26-032824.md) | [9.5](/filings/0001140361-26-012030.md) | [9.3](/filings/0001140361-26-032824.md) | [3.9](/filings/0001140361-26-032824.md) | [(3.6)](/filings/0001140361-26-032824.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(7,176) d](/filings/0001140361-24-046891.md) | [(8,457) d](/filings/0001140361-25-010717.md) | [(9,938)](/filings/0001140361-25-018967.md) | [(8,858) d](/filings/0001140361-25-030825.md) | [(8,000) d](/filings/0001140361-25-041976.md) | [(8,234) d](/filings/0001140361-26-012030.md) | [(9,032)](/filings/0001140361-26-021286.md) | [(9,101) d](/filings/0001140361-26-032824.md) | [(5,916) d](/filings/0001140361-25-041976.md) | [(3,703) d](/filings/0001140361-26-012030.md) | [(4,372)](/filings/0001140361-26-021286.md) | [(2,793) d](/filings/0001140361-26-032824.md) |
| Capital expenditure | $k | [0.0 d](/filings/0001140361-24-046891.md) | [0.0 d](/filings/0001140361-25-010717.md) | not reported | not reported | [0.0 d](/filings/0001140361-25-041976.md) | [0.0 d](/filings/0001140361-26-012030.md) | not reported | not reported | [0.0 d](/filings/0001140361-25-041976.md) | [0.0 d](/filings/0001140361-26-012030.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [28.5](/filings/0001140361-23-053242.md) | [30.4](/filings/0001140361-24-026295.md) | [30.8](/filings/0001140361-24-037067.md) | [30.9](/filings/0001140361-24-046891.md) | [34.8](/filings/0001140361-25-018967.md) | [36.7](/filings/0001140361-25-030825.md) | [36.8](/filings/0001140361-25-041976.md) | [40.5](/filings/0001140361-26-021286.md) | [45.9](/filings/0001140361-26-032824.md) | [46.9](/filings/0001140361-25-041976.md) | [55.5](/filings/0001140361-26-021286.md) | [55.7](/filings/0001140361-26-032824.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 55,971,338 at 2026-08-06, from the cover of the [10-Q filed 2026-08-13](/filings/0001140361-26-032824.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.